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With breast cancer affecting one out of every nine women.
in the United States in their lifetime and a 50%
mortality rate among those who have the disease, efforts
have been initiated to find a prophylactic regimen which
would decrease a women's chances of developing breast
cancer.

·The central purpose of this study was to

characterize the influence of moderate levels of exercise
on the induction and development of estrogen dependent
and independent rat mammary tumors.

This

characterization was compared against the known
antiestrogenic effects of tamoxifen.

The tumor model

used was 7,12-dimethylbenz(a)anthracene (DMBA) induction
of rat mammary cancer.

Hormone dependency was determined

by observing tumor growth following oophorectomy.
Although the results of the experiments yielded no
indication of tumor inhibition due to the exercise
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regimen, rats treated with tamoxifen showed a significant
reduction in body weight and mammary tumorigenesis.

In

the control group, an equal number of hormone-dependent
and ho~mone~independent tumors were·seen following
removal of the ovaries.

In the ·exercise group, a

selection against hormone-independent tumors was
observed.
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INTRODUCTION

With one out of eight women developing breast
cancer, mammary carinoma is the most common form of
cancer affecting women in the United States.

Since 1980,

the~e had been a steady 2% increase in the incidence of
breast cancer, but recently the incident rate has leveled
off at approximately 182,000 new cases per year.

The

prevalent use of mammography for early detection during
this period is believed to be responsible in part for the
rise.

The balance of cause for the rise remains unknown.

Approximately 46,000 women per year will die from a
metastatic progression of the disease (American Cancer
Society 1994).
In light of the inability to lower the mortality
rate, attention and effort of scientists and clinicians
has turned toward reduction of the incidence of breast
carcinomas (Bernstein et al., 1992; Kelsey 1993).

New

prognostic techniques (Gail et al., 1989) and the
discovery of the breast cancer linked genes, BRCAl and
BRCA2,

(Miki et al., 1994; Furteal et al., 1994; Wooster

et al., 1994) have facilitated the possiblity that women
with a higher individual risk could be targeted for
prophylactic treatment.
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A proposed intervention strategy involved the use of
the adjuvant therapeutic agent tamoxifen, which had been
succesfully used to prevent tumor recurrence in breast
cancer patients (NATO, 1985).

Tamoxifen, a non-steroid

antiestrogen, blocks the stimulatory effects of estrogen,
which is considered the primary promoter in estrogendependent and early, estrogen-independent tumor cell
lines. Due to tamoxifen's demonstrated ability to
suppress recurrence in cancer patients, the Breast Cancer
Prevention Trial was initiated to compare benefits of
tamoxifen's prophylactic use versus the possible side
effects in women who are assessed to have a high risk of
developing breast cancer (Bush

&

Helzhlsouer 1993;

Kelsey, 1993; NSABP, 1992).
An alternate strategy of prevention has been a

proposed alteration in lifestyle factors associated with
breast cancer.

Changes in components of everyday life,

such as diet and exercise, have been the focus of many
researchers because a concern over the ramifications of
sustained hormonal manipulation (Bernstein et al, 1993).
Exercise has received attention because laboratory and
epidemiological evidence has shown an associated
reduction in breast cancer incidence.

Despite this

evidence, little is known about the cause and effect of
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the relationship between exercise and breast cancer
incidence.

Breast Cancer
Breast carcinomas originate from the transformation
of the epithelial cells which line the lobules and ducts
of the breast.

Seventy to eighty percent of breast

tumors are ductal in origin (American Cancer Society,
1987).
Transformation occurs when the cell's genome is
altered resulting in a failure of the mechanisms which
regulate the cell cycle. In order for a tumor to develop
from a single transformed cell, cell division must occur.
Each cell cycle results in the passing on the altered
chromosome, compounding the damage to the chromosome
and/or altering chromosomal distribution.

Cell division

in tissues like the mammary epithelium is influenced by
endogenous hormones or exogenous analogs.

Epidemio-

logical observations, such as the increased risk
associated with early menarche, late first full-term
pregnancy, and the use of postmenopausal estrogen
replacement therapy, indicate that ovarian hormones have
a central role in the initiation and promotion of breast
cancer (Am. Red Cross, 1994).

Menstrual cycling and
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pregnancy events are marked by large changes in the
ovarian hormones estrogen and progesterone (Berstein

&

Ross, 1993).
Growth of the mammary tissue occurs during two
hormone dependent events, puberty and pregnancy.
Although both processes are stimulated by estrogen,
progesterone, insulin, cortisol, and prolactin, the
timing and concentration of exposure to these hormones
result in the distinct changes occurring between the
events.

Estrogen has a key role in puberty where it

potentiates the action of prolactin and its concentration
directly influences the growth and development of mammary
tissue (Speroff et al., 1994).

In the animal models,

estrogen has been demonstrated to have a direct effect on
mammary epithelial cell development by stimulating growth
and branching (Silberstein et al., 1994; Halsam, 1988;
Daniel et al., 1987).
Estrogen- and progesterone-dependent changes in
mammary tissue occur during normal menstrual cycles.
During late luteal phase, stimulation by elevated levels
of estrogen and progesterone results in maximal breast
size.

Increases in fluid secretion, mitotic activity

and gene expression of nonglandular tissue and glandular
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epithelium mark this period of size increase in the
luteal phase (Speroff et al., 1994).
The predominant estrogens circulating in the blood
are estradiol-17P and estrone.

Estradiol-17Phas been

demonstrated to be the most biologically active form of
estrogen in mammary tissue (Pasqualini, et al, 1991).
During premenopausal years, almost all estrogen is
ovarian in origin with estadiol-17P in higher plasma
concentrations than estrone.

After menopause, direct

production of estrogen by the ovaries ceases.

Most

postmenopausal estrogen arises from the aromatization of
adrenal androgens to estrone.
metabolized into estradiol.

In turn, some estrone is
The postmenopausal plasma

·concentrations of estrone are significantly higher than
estrogen (Bernstein

&

Ross, 1993).

Mammary tumors are normally characterized in part by
estrogen dependence or independence.

Measurements of the

level of estrogen receptors in tumors are used in
prediction of patient prognosis and viability of
antiestrogen adjuvant therapy.

Though clinical assays

can produce qualitative and quantitative measurements of
tumor ER, tumor hormone sensitivity does not correlate
precisely with estrogen receptor status.

Over 60% of

human breast tumors are estrogen receptor positive (ER+)
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and only two-thirds of these ER+ tumors are expected to
be controlled by antiestrogen therapy.

Further, 5-10% of

estrogen receptor negative (ER-) assayed tumors have
proven to be sensitive to antiestrogen therapy
(Pentrangeli et al., 1994; McClelland et al., 1987;
McClelland et al., 1986; Osborne et al., 1980; DeSornbre
Jensen, 1980; Paridaens et al., 1980;

&

Wittliff et al.,

1980). Despite the discrepancy between ER status and
estrogen sensitivity, the value _of the ER assay was
elucidated by the relativity low percentage of ER+ cells
in normal tissue, which is less than 20 percent (Ricketts
et al., 1991; Peterson et al., 1987).

Petrangeli et al.

(1994) studying breast carcinoma biopsies found a
significantly higher percentage of ER+ postive cells in
neoplastic tissues (75%) compared to perineoplastic
tissue (57%), and that there was a positive association
between ER expression and ER gene hypomethylation.
Normal methylation of the estrogen receptor gene can
inhibit the expression of the receptor. The elevated
expression of the ER in neoplastic tissue indicates the
significance of estrogen in the pathogenesis of most
breast cancers.
Through interaction with the estrogen receptor,
estrogen mediates many cellular activities essential for
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tumor growth.

Estrogen triggers DNA synthesis and gene

transcription in normal and cancerous mammary cell lines.
Release of growth stimulating, autocrine and paracrine
polypeptides, such as tranforming growth factor-a,
epidermal growth factor (Bates et al., 1988; Imai et al.,
1982), insulin-like growth factor-II (Brunner et al.,
1993; Osborne et al., 1989)and platelet-derived growth
factor (Rosengurt et al., 1985.), has been shown to be
increased with estrogen stimulation.

Conversely, a

reduction in the levels of the inhibitory factor,
transforming growth factor-~ was affected by estrogen in
the tumor cells (Knabbe et al., 1987).
Animal studies have demonstrated that estrogens have
a positive influence on the induction and promotion of
mammary tumors in animal studies and that reversal of
this influence can be achieved by oophorectomy or
treatment with antiestrogens (Doa, 1981; Jordan, et al,
1990; Jordan et al 1980).
Epidemiological studies have shown that breast
cancer risk increased in women having frequent,
relatively short menstrual cyles (Pike et al., 1993;
Whelan.et al., 1992;

Henderson et al., 1985).

Women

with these frequent ovulatory cycles are believed to be
at higher risk because more of their reproductive years
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are spent in the luteal phase than women having less
frequent ovulatory cycles.

The high mitotic activity

that marks the luteal phase is considered to be the
source of the elevated risk.

Consquently, women who

experience anovulation or amenorrhea are shown to have a
reduced risk of mammary cancer (Pike et al., 1993;
Whelan.et al., 1992).

Mechanism of Steroid Action
The mechanism of steroid action can be demonstrated
by the pathway of agonism of the estrogen hormones
(Fiqure 1).

Estrogen influences the activity of the

target cell through a mechanism centered around the
nuclear, estrogen receptor (ER).

The hydrophobic,

estrogen molecule is carried to mammary tissue by a sex
hormone binding globulin (SHBG).

The estrogen molecule

becomes biologically active by dissociating from SHBG and
diffusing through the lipid bilayer of the plasma
membrane.

The steroid passes through the cytosol and

transverses the nuclear membrane.

In the nucleus, the

estrogen binds to the ER altering the conformation of the
receptor (Figure 1).

This comformational change causes

the release of a heat shock protein and activates the
receptor.

The activated ER-estrogen complex then
8

dimerizes with another activated ER-estrogen complex.
The dimer binds to the estrogen response element (ERE) on
the target chromosome.

Dimer binding to the ERE and

interaction with RNA polymerase promotes the
transcription of the estrogen-mediated gene downstream.
The products of these genes potentiate the actions
associated with estrogen stimulation (Tsai and O'Malley,
1994) .
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Figure 1:

Mechanism of steroid action modified from Tsai
and O'Malley (1994). SHBG=sex steroid binding
globulin, HSP=heat shock protein, mRNA=
messenger ribonucleic acid, DNA= deoxyribonucleic acid.
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Tamoxifen
Tamoxifen (Fig. 2),

[ZJ-2-[4-(1,2-diphenyl-1-

butenyl)-phenoxyl]-N,N-dimethylethanamine, is a nonsteroid, antiestrogen first synthesized in 1966 (Harper
MJK

&

Walpole AL, 1966).

During the 1970s, it was

discovered that tamoxifen demonstrated antiestrogenic and

Figure 2:

Tamoxifen molecule. Functional group R
represents hydrogen in the basic molecule and
a hydroxyl group in trans 4-hydroxy-tamoxifen.
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antitumor behavior in rat models (Jordan, 1974; Cole et
al., 1975; Nicholson

&

Golder, 1975; Jordan et al., 1978)

and humans (Cole et al., 1971).

Since then, numerous

trials have shown tamoxifen's ability to decrease cancer
recurrence and patient mortality rates (Bush &
Helzlsouer, 1993).

In recent years, tamoxifen has been

proposed as prophylactic breast cancer agent for use by
women, who have family history or genetic disposition
toward developing a mammary carcinoma.
The chemopreventative properites of tamoxifen have
been demonstrated in animal models.

Jordan et al,

(1976)

noted a reduced tumor number and increased time of
appearance in a DMBA-induced mammary tumor model with use
of tamoxifen.

Parallel observations were made in the

nitrosomethylurea (NMU)-induced mammary carcinoma model
(Turcot-Lemay

&

Kelley, 1980).

Long term tamoxifen use

has been demonstrated to suppress tumor genesis (Jordan
et al., 1991).

Further, tamoxifen reduced by 90% the

number of spontaneous tumors in a study of older rats
(Maltoni et al., 1988).
Tamoxifen has been shown to be an effective
antitumoral and chemopreventative agent in mammary
tissue.

Elucidation has shown that it is a cytostatic

agent, not a cytotoxic agent (Jordan, 1994).
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Studies in

vitro with human cancer cells, such as the MCF-7 cell
line, have shown that tamoxifen inhibits transition from
the G0 -G1 phase resulting in suppression of cell cycling.
This cytostasis produces an increase in the number of
cells in G0 -G1 phase and a decrease in number of cells in
S, G2, and M phase in the cell cultures (Taylor et al.,
1983; Sutherland et al., 1983; Osborne et al., 1983).
Using

3

[H]-thymidine assays, Osborne et al. (1992) showed

that preneoplastic cell lines were less proliferative in
an animal under a tamoxifen protocol.

Additionally,

removal of tamoxifen therapy from animals that have been
transplanted with a cancer cell line resulted in the
appearance of tumors (Jordan et al., 1991).
The cytostatic influence on cancer development when
tamoxifen is used prophylactically may select against
estrogen-responsive cells producing a higher percentage
of the more aggressive, estrogen-independent tumors.
Zimniski and Fendl (1992) studying animals receiving
coincidental doses of tamoxifen and a carcinogen
witnessed a reduction in the total tumor incidence and
100% selection of hormone-independent tumors.

Sylvester

et al. (1987) showed an 3-fold increase in the percentage
of estrogen-independent tumors in a study with a
prophylactic dosage of tamoxifen in a DMBA rat model.

13

With respect to tamoxifen's antitumoral properties,
interaction with the estrogen receptor is central to the
antiestrogens influence.

While tamoxifen has a very low

affinity for the ER, one of its metabolites, trans 4hydroxy-tamoxifen (Figure 2), has an affinity for the ER
nearly equal to that of estradiol (Kemp et al., 1983).
The binding of the receptor by the metabolite blocks the
agonistic activities associated with normal estrogen-ER
interaction (Jordan et al., 1977; Allen et al., 1980;
Borgna

&

Rochefort, 1981).

Molecular analysis has shown

that the tamoxifen molecule fits into the estradiol
binding pocket on the ER.

The pocket contains a number

of hydrophobic residues and a glutamate residue.

The

phenolic group of 4-hydroxytamoxifen occupies the same
position relative to the hydrophobic groups as the A-ring
of estradiol, but the glutamate residue is unable to
hydrogen bond with the antiestrogen molecule.

The long

nitrogen-containing side chain inhibits interaction
between arginine and aspartate residues of the ER
necessary for its activation (Lewis et al, 1995).

This

positioning in the ER blocks estradiol binding without
activating the receptor.

Estrogen-related gene

activation is blocked by the tamoxifen-ER complex, which
is not capable of dimerizing with other activated
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complexes and blocking estrogen-ER mediated cell
stimulation.

Exercise
Exercise has been demonstrated to have beneficial
effects on a number of disease processes, such as those
of cardiovascular disease, diabetes, osteoporosis, and
colorectal cancer (Friedenreich and Rohan, 1995).

These

observations have raised a debate as to whether or not
exercise would have an influence on the processes that
govern the etiology of cancer.

The influence of exercise

on the disease processes of breast cancer is believed to
be due to the 1) alterations in the energy balance, 2)
endocrine system effects; and 3) stimulation of the
immune system (Thompson 1992).

The influence on breast

cancer has been studied in both animal and
epidemiological studies.
Exercise is physical activity specifically designed
to improve physical fitness.

There are three primary

components of physical activity:

duration, the length of

the exercise bout; intensity, the work-rate of the
exercise bout; and frequency.

Aerobic exercise is

characterized by a duration of at least 15 to 20 minutes;
a frequency of at least 3 to 4 times a week; and an
15

intensity that will lead to improvement of aerobic
capacity.

Aerobic capacity cdn be measured by an

improvement in maximal oxygen consumption,
V02max. (Caspersen, 1989).
In the rodent model, the effect of exercise during
tumor initiation (commonly considered to be the first
seven days after carcinogen administration (Thompson,
1994) and/or promotion phases of tumor development have
been tested.

Exercise begun during the initiation phase

has been shown to decrease tumor incidence (Yedniak et
al., 1987; Sakamoto et al., 1992; Moore and Tittle, 1973)
or have no effect (Thompson, 1994).

Studies with

exercise protocols beginning during the promotional phase
have yielded either decreases (Cohen et al., 1992;
Bennick et al., 1986; Cohen, et al., 1988; Thompson,
1994; Thompson et al., 1995) or increases (Thompson et
al., 1988;

Thompson et al., 1989) in the proportional

incidence of tumors in the animals.

The discrepancy in

experimental results may be due to differences in
protocols with respect to duration and intensity.

Energy

balance, endocrine, or immunological alterations may be
subject to the demands of the protocol.
Caloric expenditure of an exercise bout is a
function of the duration and intensity of the activity.
16

As the caloric expenditure rises, the greater the effect
it has on the body's energy balance.

Thompson (1992)

demonstrated a negative relationship between caloricexpenditure and tumor indicidence.

However, this

assertion is challenged by the fact that in two studies
Thompson et al. (1988; 1989) found no significant changes
in carcass size or composition.

Additionally, the purely

caloric basis theory was confounded by the experiments of
Thompson et al. (1995), which demonstrated a link between
intensity and reduced tumor incidence.

In that study

carcinogenesis inhibition required an intensity that was
70% maximal and had no correlation with caloric

expenditure.

This last study suggests that there is an

intensity threshold where caloric expenditure has a
greater influence on mammary carcinogenesis (Thompson et
al., 1995)
Another explanation for the discrepancy between the
studies may be related to the altering of endocrine
function.

Thompson et al.,

(1995) stated that the

duration of exercise had a greater effect than intensity
on lengthening the animals' estrous cycle.

A study using

exercised rats which monitored varying intervals,
indicated that extensive exercise induced changes in the
frequency of release and strength of gonadotropin
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releasing hormone and lutenizing hormone leading to
amenorhea (Manning and Bronson, 1991).

The expected

luteal dysfunction or amenorhea resulting from the
changes in the release patterns would lead to a
significant reduction in levels of estrogen stimulating
the mammary tissue and carcinomas.
Most epidemiological studies in humans have
generated results favoring the role of exercise or high
levels of physical activity in the reduction of breast
cancer risk, but contradictory evidence does exist.

A

study of the alumnae of 10 American colleges showed a
decreased risk for athletes when compared to non-athletes
(Fisch et al., 1987).

Other studies focusing on the

breast cancer risk when compared with the level of
caloric expenditure showed a decreasing incidence in
breast cancer as the caloric demand of exercise increased
(Bernstein et al., 1994; Friedenreich and Rohan, 1995).
Further studies have shown that women in occupations with
a high level of physical activity also benefited from a
lowered incidence of breast cancer (Zheng et al 1993;
Vena et al., 1987).

In opposition to these observations,

the Farmingham Heart Study (Dorgan et al., 1994) and the
American Cancer Society's Cancer Prevention (Garfinkel
and Stellmanm, 1988) cohort studies
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observed an

increased risk of breast cancer with increased physical
activity.
During reproductive years, exercise has been shown
to alter the pattern of regular menstrual cycling leading
to a reduction in breast cancer incidence.

Prospective

studies where menstrual cycling characteristics were
studied before and after training, demonstrated that
exercise, especially strenuous exercise, can induce
anovulation and luteal dysfunction, oligomenorrhea, and
amenorrhea (Greene, 1993; Loucks, 1990;
Rogol, 1990).

Keizer and

These interruptions of the menstrual cycle

are believed to be the result of alterations in the
hypothalamic-pituitary-ovarian axis, which lead to
changes in levels and pulsatile release of GnRH and LH
(Thompson, 1992; Greene, 1993; Loucks, 1990;

Keizer and

Rogol, 1990).

Problem Statement
The objective of this _study was to establish the
influence of a moderate exercise regimen on the induction
and growth of 7,12-dimethylbenz(a)anthracene induced,
estrogen-dependent and.independent rat mammary tumors.
Parallel protocols involving the use of tamoxifen served
to assess the reduction of tumor incidence and influence
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on estrogen dependence of exercise.

Estrogen dependence

was determined by changes in tumor volume preceeding and
following oophorectomy.

Hypothesis
Prophylactic regimens of exercise and tamoxifen will
inhibit the induction and growth of mammary tumors
induced by the introduction of 7,12-dimethylbenz(a)
anthracene (DMBA).

Specifically, exercise will have a

broad inhibition on both estroge_n-dependent and
independent tumor cells;

tamoxifen will have an

influence on tumor growth and development with a greater
effect on the estrogen-dependent tumors;

and the two

regimens in combination will have an additive effect on
the inhibition of mammary tumor induction and growth.
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METHODS AND MATERIALS

Animals
Forty-two female, Sprague Dawley rats (Harlan
Sprague Dawley, Inc.) between 32-34 days of age, were
housed two per cage in the Lappin Hall Animal Care
Facility.

They were placed on a 12 hour light/ 12 hour

dark photoperiod.

The rats were fed Purina Rodent Chow

(Ralston Purina Company) and water ad libitium. The
animals were maintained in the Lappin Hall Animal Care
Facility.
Prior to the experiment, the animals were randomly
divided and segregated into four groups:

Group I-10 rats

in the control group; Group II-11 rats in the exercise
group; Group III-10 rats in the tamoxifen group; and
Group IV-11 rats in the tamoxifen & exercise group.
Group I was administered both the exercise sham and
tamoxifen sham protocols.

Group II underwent the

moderate exercise and sham tamoxifen protocols.

Group

III received the experimental tamoxifen regime and sham
exercise.

Group IV

was maintained on active exercise

and tamoxifen protocols (Figure 3.)
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Figure 3: Flow chart of research protocol by day.

1. Begin
exercise protocols. 2. Begin tamoxifen protocols.
3. DMBA administration. 4. Oophorectomy.
5. Sacrifice.
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Exercise
Rats of the Group II and Group IV were placed on a
moderate exercise regimen (Thompson, et al, 1989) ten
days before the introduction of carcinogen.

The animals

were exercised on a motorized treadmill (Lafayette
Instruments, Inc.) using electric shock as motivation.
The established regimen consisted of five, 15-minute
exercise bouts per week with a belt speed of 20 meters
per minute and inclination of 1°.

To introduce the

animals to treadmill running, the first five days of the
experiment were marked by increasing speed and duration:
day one (day -10 with respect to carcinogen introduction)
at 8 meters/minute, 3-5 minutes; day two at 12
meters/minute, 10 minutes; day three at 12 meters/minute,
15 minutes; days four and five at 16 meters/minute for 15
minutes.

The animals were run during the light period to

insure that the activity was extracurricular to normal
activity.

This protocol was continued to the day 100

when the animals were sacrificed (Fig. 3).
Group I and Group III were maintained on sham
treatment.

The sham treatment involved placing the

animal's cages into direct light for 15 minutes.

This

was done to equalize the stress of the control animals
with those exercising on the unshaded treadmill.
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Tamoxifen
The Group III and Group IV were started on a
prophylactic regimen of tamoxifen citrate three days
before carcinogen introduction.

Each animal was

administered 100 micrograms of tamoxifen citrate (Sigma
Chemical Co.) in 0.1 ml peanut oil vehicle (Sigma
Chemical Co.) five days a week (Osborne, 1992).

After

being suspended in a peanut oil vehicle using vigorous
stirring, tamoxifen citrate was administered to the rats
via subcutaneous injection using a 1.0 ml tuberculin
syringe and 26 gauge needle.

The tamoxifen protocol was

continued until the animals were sacrificed (Fig 3).
Groups I and Group II were given subcutaneous
injections of 0.1 ml of peanut oil on a schedule
synchronous with the tamoxifen-administered groups.

Carcinogen Administration
On experimental day O, the animals (age
approximately 49-50 days) received 10 mg dose of 7,12dimethylbenz(a)anthracene (Sigma Chemical Co.) dissolved
in 1.0 ml of sesame oil (Sigma Chemical Co.).

After

light etherization, each animal was administered the DMBA
via gastric intubation and injection with a 10 ml
syringe.
24

Tumor Palpation
The date of carcinogen introduction was marked as
day 0 with respect to the initiation of tumor
development.

Four weeks after the administration of DMBA

introduction, the animals were checked daily for palpable
tumors.

Newly discovered tumors were recorded on the

basis of individual rat identity, date of discovery and
anatomical position.

Oophorectomy
Eighty-six days after carcinogen administration, an
oophorectomy was performed on those animals with palpable
tumors.

All animals were anesthetized using 4 mg of

sodium pentobarbital per 100 gm of body weight (Sigma
Chemical Co.) dissolved in 0.1 ml distilled H2 0.

The

ovaries of tumor bearing rats (TBR) were removed via
bilateral, dorsal incision.

The animals were given four

days to rest before resumption of tamoxifen and exercise
regimens.

Tumor Measurement and Comparison
While anesthetized, the tumors of TBRs were measured
using Vernier calipers.

Measurements of the diameter
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were taken for each tumor along three major axes and
volumes calculated using the following equation:
4/3*n*Radiusl*Radius2*Radius3.

Volume=

The calculated volumes

were compared to ones taken two weeks later at sacrifice
(Day 100).

A decrease in tumor volume of

greater than

20% over the two week period was given to indicate
estrogen dependency (Fendl

&

Zimniski, 1992).

Statistical Analysis
Statistical evaluation of the experimental data were
tested for significance using the Student's t-test a
level of

significance of p<0.05.
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RESULTS

Pre-Oophorectomy

Mean Animal Mass
Animals were weighed on day 86 just prior to
oophorectomy.

Comparison of the mean group masses showed

a significant difference between the values for groups
receiving the tamoxifen protocol and those that were
receiving the peanut oil control (Figure 4).

Larger mean

masses were seen in the Group I (Control) and Group II
(Exercise), which had 254g +/- 7.4g and 254g +/- 7.0g,
respectively.

Rats in Group III (Tamoxifen) and Group IV

( Tamoxifen-Exercise) showed mean group masses of 211g
+/- 7.7g and 203g +/- 6.4g.

Cross comparisons using

Student's t-test indicated a significant difference
(p<0.05) between either Group I or Group II groups and
Group III or Group IV.

Tumor Appearance
During the period between carcinogen introduction
and oophorectomy, animals were examined for palpable
tumors.

Tumor appearance data for the experimental

groups was characterized by a day-to-day progression in
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Figure 4:

Mean animal mass of the control, exercise,
tamoxifen, and tamoxifen-exercise groups 86
days after DMBA adminstration.
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number of tumor bearing rats (TBR) per group (Figure 5).
Animals were added to the respective group's cumulative
number of tumor bearing rats at the date of appearance of
the first palpable tumor.
Group I yielded the most tumor bearing rats with
six of ten animals having developed tumors during the

observation period.

The first palpable tumor appeared 47

days after carcinogen introduction.

The remaining five

animals had first tumors palpated at day 52; day

53, two

rats; day 59 and day 73.
Five out of eleven animals palpated tumors in the
Group II.

First tumor appearance date for the exercise

group was on day 53.

The other four Exercise group tumor

bearing rats palpated tumors on day 55, day 58, day 61
and'day 70.
During the pre-oophorectomy observation period, the
Group III had one tumor bearing rat in the experimental
group of ten.

This animal had the earliest palpable

tumor appearance date, day 41.
The Group IV had one tumor bearing rat out of eleven
animals.

This tumor was palpated on day 45.
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Figure 5:

Control, exercise, tamoxifen, and tamoxifenexercise rats with palpable tumors based on
the day of first tumor appearance
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Group Tumor Information
Tumor data for experimental groups was accumulated
for pre-oophorectomy period. Groups were compared on the
basis of tumor bearing rats per group, average number of
tumors per TBR, and total number of tumors (Table 1).
There was found to be a significant difference in TBR per
group between the either Group I or Group II and Group
III or Group IV with respect to TBR per group.

Table 1:

Group tumor data for pre-oophorectomy tumor
bearing rats ( TBR) .
TBR per
Group

Tumors
per TBR

Tumors per
Group

Control
(n=l O)

6/10

2.17

13

Exercise
(n=ll)

5/11

1.20

6

Tamoxifen
(n=lO)

1/loa,b

1.00

1

Tam-Ex
(n=l 1)

1/11 a,b

1.00

1

a=significant difference from the control group at p<0.05
b=significant difference from the exercise group at
p<0.05
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Post-oophorectomy

Group Tumor Information
Post-oophorectomy tumor data for the experimental
groups were collected on the sacrifice date.

The values

were similar to that of pre-oophorectomy with a few
exceptions (Table 2).

The Group I had two tumors arise

in an animal that had been oophorectomized.
unoophorectomized animal in the Group
tumor on day 90.

An

III developed a

Finally, a loss of three animals while

under anesthesia diminished the size of the Group II from
eleven to eight animals.

No significant differences were

found with statistical analysis.
Table 2:

Group tumor data for post-oophorectomy tumor
bearing rats (TBR).
TBR per
Group

Tumors
per TBR

Tumors per
Group

Control
(n=l0)

6/10

2.50

15

Exercise
(n=8)

2/8

1.00

2

Tamoxifen
(n=l0)

2/10

1.00

2

Tam-Ex
(n=ll)

1/11

1.00

1
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Estrogen Dependence and Independence
Determination of estrogen dependence or independence
of tumors was done by a comparison

of pre-oophorectomy

tumor volume measurements with the post-oophorectomy
volumes which were measured at sacrifice.

Indication of

estrogen dependence was established by a 20% decrease in
volume over the two-week period (Fendl

&

Zirnniski, 1992).

Tumors that appeared in the oophorectomized Group I
animal were perceived to be estrogen independent because
of their growth in an estrogen poor environment.

The

late ~rising tumor in the unoophorectomized Group III
animal could not be classified.

Additionally, no

determination could be made for the tumors of the dead
Group II animals.
Compiled estrogen dependence/independence data for
the experimental group showed mixed results (Table 3).
Group I animals were divided nearly equally between
independent and dependent tumors.

Even if the two late

appearing tumors were disqualified, the division would
still remain nearly equal with 7 dependent and 6
dependent tumors.

With this trend in evidence, a fifty-

fifty distribution between dependence and independence
was used for assessment of the other tumor distributions.
Analysis of the Group II tumor distribution was
significantly hindered by the loss of the three animals
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and their collective four tumors.

The remaining animals

showed a prevalence toward the development of estrogen
dependent tumors (Table 3).
The Group III had just one tumor bearing rat.

This

rat had developed an estrogen dependent tumor, which
seemed unusual in the presence of the antiestrogen
tamoxifen.
The Group IV had a single tumor bearing animal with
one tumor.

The estrogen independent classification of

this tumor met expectations in this tamoxifen-treated
animal (Table 3).
Tab~e 3: Assessment of estrogen dependence and

independence of animal tumors.
Estrogen
Dependent
Tumors

Estrogen
Independence
Tumors

Control
(n=l O)

7

8

15

Exercise
(n=8)

2

0

2

Tamoxifen

1

0

0

l

Total
Tumors

(n=lO)

Tam-Ex

1

(n=l 1)

* One tumor developed in this animal that had not been
oophorectomized.
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Estrogen Dependence Vs. Appearance Time
Comparison

of estrogen status, dependent or

independent, with palpable-tumor appearance time yielded
no observable trend.

An examination of only the Group I

distribution and appearance times also failed to yield
any trend with respect to palpable appearance time and
estrogen status.
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DISCUSSION

The infuence of exercise on the estrogen levels in
the body and on the estrogen dependent/independent status
of developing mammary tumors is largely unclear except
for menstrual and ovarian cycle changes resulting from
regimens involving intense, extended physical activity
(Greene, 1993; Loucks, 1990; Keizer and Rogol, 1990).
The estrogen dependent effects of moderate exercise
levels remain uncharacterized.
Sustained exercise is considered to be an essential
component in proper weight control programs, but in this
study, the tamoxifen protocol not the exercise protocol
was associated with a significantly lower body weight
when compared to the controls (Figure 1).

The observed

lack of change in the exercise group body weight is
consistent with other studies where no significant change
in rat body weight and composition was seen in animals on
similar exercise protocols when compared to controls
(Thompson et al., 1988; Thompson et al.,1989).

In

looking at tamoxifen's effect of body weight, Wade and
Heller (1993) observed that tamoxifen in dose-dependent
fashion reduced body weight.

They attribute this

phenomena to a dose-dependent hypophagia; a decreased
lipoprotein lipase activity, the blocking of estrogen
receptors in adipose tissue, the associated reduction in
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amount of adipose tissue; and as yet an uncharacterized
interaction with the ER receptor in the brain and
throughout the body.

Examination of the body mass data

from this study has indicated that tamoxifen's effects on
body mass in the rat models are more pronounced than
those of moderate exercise.
Tamoxifen's antiestrogenic and antitumoral
properties led to its use in adjuvant breast cancer
therapy and consideration for use in prophylaxis.

The

group tumor data demonstrated the antitumoral activity
with the tamoxifen protocol producing a significant
reduction in the number of tumor bearing animals within
the respective groups when compared to the exercise and
control groups (Table 1).

In contrast to the

antiestrogenic activity, a mixed result was seen in tumor
dependence.

As would be expected, the single TBR of

Group IV (tamoxifen and exercise) developed an estrogen
independent tumor, but the Group III (tamoxifen) TBR had
one estrogen dependent tumor (Table 2).

The dependent

tumor's resistance to tamoxifen may be the result of
estrogen receptor mutation,

sequestering of tamoxifen by

an antiestrogen binding sites, or metabolism of tamoxifen
to a less antagonistic isomer (Osborne and Fuqua, 1994;
Jordan, 1994; Pavlik et al., 1992).
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Development of

resistant tumors is one of the chief concerns in use of
tamoxifen prophylaxis.
As the body adapts to exercise, marked changes in
metabolism occur.

One of the expectations of this study

was to determine whether these adaptations have an
influence on the tumor growth and induction.

When

compared to the control group data, the pre-oophorectomy
numbers for the exercise group indicated that there was a
decreased number of tumors per tumor bearing rat.
However, in looking at the number of TBR per group or the
first tumor appearance times of those tumors, the
difference is less prominent.

These differences in tumor

pre-oophorectomy tumor data could be a result of altered
hepatic metabolism associated with exercise which would
effect the oxidase-dependent activation of the
procarcinogen DMBA (Thompson, 1994; Dssing, 1985;
Rosenblooom and Sutton, 1985).
Unfortunately, the loss of three out of five tumor
bearing animals in exercise group compromised the most
novel objective of this study, the determination of the
influence of moderate exercise on the endocrine
sensitivity of breast tumors.

The tumors in surviving

animals were both estrogen dependent.

If this partial

observation was evidence of the whole, it would favor a
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mechanism of influence for exercise which is not
integrally related endocrine activity.

Continuing the

supposition based on the partial result, it is apparent
that if the exercise protocol favored the development of
estrogen dependent tumors, tamoxifen's effects as
demonstrated in combination group overrode this selective
influence.
A certain amount of ambiguity surrounds the study of
the effects of exercise on mammary tumor etiology because
of the broad physiological changes and adaptations that
result from an extended regimen of exercise.

The aim of

this study was to establish the influence of a moderate,
prophylactic exercise regimen on estrogen-dependent and
independent rat mammary tumors and to assess this
influence using parallel prophylactic protocols using
tamoxifen. The hypothesis tested stated that exercise
would have a broad inhibition on both estrogen-dependent
and independent tumor cells;

tamoxifen would have an

influence on tumor growth and development with a greater
effect on the estrogen-dependent tumors;

and the two

regimens in combination would have an additive effect on
the inhibition of mammary tumor induction and growth.
Though the moderate exercise regimen failed to
significantly inhibit tumor growth and development when
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compared with the tamoxifen protocol, the indication of a
selection toward estrogen-dependent tumors does suggest
that exercise does in some way influence the development
of the mammary tumors. Despite the endocrine-based
classification of the tumors, it is not clear whether
this selection is completely or partially estrogen
related.
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CONCLUSIONS

The objective of this study was to establish the
influence of a moderate exercise regimen on the induction
and growth on the induced estrogen-dependent and
independent rat mammary tumors.

Examination of the hypo-

thesis shows that the results of the" experiment were
different from the projections.

The moderate exercise

regimen did not inhibit tumor growth and appeared to
select against estrogen-independent tumors.

The

tamoxifen protocol did significantly inhibit tumorgenesis
but did not select for independent tumors.

Finally, the

combination prophylaxis demonstrated no additive tumor
inhibition.

In this study, moderate exercise in

prophylaxis demonstrated no tumor inhibition and a
selective pressure favoring estrogen-dependent tumors.
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